Physician profile
Debra C Webb
NPI 1164539763
$1,779.54
in general payments reported to CMS, 2019-2025
14 companies · $728 in 2025
The $728 reported for 2025 was more than what 86% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2020: $219 · 2021: $41.20 · 2022: $146 · 2023: $222 · 2024: $301 · 2025: $728.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,233 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,232.63 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $574.32 | 2023-2025 | Infuse, Vyzulta, Envista Aspire Iol |
| Alcon Vision LLC | $327.18 | 2019-2025 | Precision7, Precision 7 |
| Johnson & Johnson Vision Care, INC. | $243.49 | 2019-2025 | Acuvue |
| Sun Pharmaceutical Industries INC. | $130.03 | 2019-2025 | |
| Tarsus Pharmaceuticals, INC. | $115.25 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $98.54 | 2019-2024 | |
| Oyster Point Pharma, INC. | $95.85 | 2022-2025 | Tyrvaya, Ryzumvi |
| Coopervision INC. | $57.24 | 2019-2024 | Myday Contact Lens |
| Abbvie INC. | $32.65 | 2022 | |
| Kala Pharmaceuticals, INC. | $32.64 | 2020 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Optos, INC. | $18.96 | 2020 | |
| Mallinckrodt Hospital Products INC. | $18.07 | 2022 | |
| Shire North American Group INC | $15.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Webb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.